- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT03544112
Emergency Department Connection to Care With Buprenorphine for Opioid Use Disorder (ED-CONNECT)
NIDA CTN-0079: Emergency Department Connection to Care With Buprenorphine for Opioid Use Disorder
The purpose of this study is to learn what resources are needed to improve outcomes for patients with opioid use disorder. The study will look at how patients engage in treatment and the decisions that patients and providers make regarding treatment, specifically buprenorphine treatment, for opioid use disorder.
The aims of this study are:
- To evaluate using mixed methods the feasibility and acceptability of OUD screening, ED-initiated BUP, and referral.
Over the course of the study and as XR-BUP is added to hospital formularies, to estimate the percentage and confidence intervals of patients assessed, treated, and engaged in treatment at Day 30. This will be a three-site study employing a multi-faceted approach to facilitate clinical protocol implementation and to assess feasibility, acceptability, and impact. Investigators will develop, introduce and update site-specific ED clinical protocols and implementation plans for OUD screening, ED-initiated BUP, and referral for treatment. A participatory action research approach will be utilized along with mixed methods incorporating data derived from:
- Medical record and administrative data abstraction,
- Research assessments involving patients who are eligible for and willing to receive ED-initiated BUP (including both those who do, and do not, receive BUP); these assessments will document the index ED visit and the 30th day after the index ED visit,
- Qualitative interviews, focus groups, and quantitative assessments involving providers and staff, patients, and other stakeholders.
Studie Overzicht
Toestand
Conditie
Studietype
Inschrijving (Werkelijk)
Contacten en locaties
Studie Locaties
-
-
New Hampshire
-
Claremont, New Hampshire, Verenigde Staten, 03743
- Valley Regional Healthcare
-
Manchester, New Hampshire, Verenigde Staten, 03102
- Catholic Medical Center
-
-
New York
-
New York, New York, Verenigde Staten, 10016
- New York University School of Medicine
-
New York, New York, Verenigde Staten, 10016
- Bellevue Hospital Center
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Bemonsteringsmethode
Studie Bevolking
Beschrijving
Inclusion Criteria:
- ED STAFF: ED/Hospital leadership and staff: Leadership and staff across multiple disciplines (e.g., nurses, social workers, physicians, NPs, PAs, pharmacist, physician and nursing directors) at each ED site will be recruited to participate in the formative evaluation and the IF.
- PROVIDERS: Community treatment providers/OTP leadership and program staff: Providers, leadership and staff involved in the provision of office-based BUP, community treatment, and/or at opioid treatment programs (OTPs) will be recruited to participate in the formative evaluation and the Implementation Facilitation.
- COMMUNITY: Other Stakeholders: Other community leaders and members (e.g., EMS, fire department, police, local government leadership, community advocacy groups, etc.) may be recruited to participate in qualitative interviews or focus groups.
- PATIENTS: ED patients will be recruited to participate in interviews or focus groups.
- PATIENT-PARTICIPANTS: ED patients who are eligible for and willing to receive ED-initiated BUP will be recruited to participate in two research visits.
- ALL ED PATIENTS: Administrative and health record data will be examined to assess rates of screening, assessment, eligibility determination, etc.
Stakeholder-Participant Inclusion Criteria
- A member of one of the stakeholder groups (1-4 above)
Patient-Participant Inclusion Criteria
Eligible for and willing to receive ED-initiated BUP
- Eligibility for ED-initiated BUP is operationally defined as meeting site clinical protocol criteria determined and documented by site clinical staff. See Section 9.2 Clinical Protocol.
- Willing to receive ED-initiated BUP is operationally defined as providing an affirmative answer to the following question, which will be embedded in each site's clinical protocol: Would you like to receive buprenorphine today?
- NOTE: Patients meeting these criteria, and not meeting exclusion criteria below, may be included as study participants regardless of whether they receive or do not receive ED-initiated BUP
Exclusion Criteria:
Stakeholder-Participant Exclusion Criteria
- Unwilling or unable to provide consent
- Currently in jail, prison or any inpatient overnight facility as required by court of law or have pending legal action or that could prevent participation in the study
Patient-Participant Exclusion Criteria
- Not able to speak English sufficiently to understand study procedures and provide written informed consent
- Unable or unwilling to provide written informed consent or to participate in study procedures
- Currently receiving any medication treatment for OUD at the time of index ED visit
- Current research participant in a substance use intervention study or previous participation in the current study
- Are currently in jail, prison or any inpatient overnight facility as required by court of law or have pending legal action or that could prevent participation in the study
- Inadequate locator information (unable to provide 2 unique means of contact)
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
Cohorten en interventies
Groep / Cohort |
Interventie / Behandeling |
---|---|
ED and OUD treatment providers and staff
|
Implementation will include developing clinical protocols containing core components of the intervention to which fidelity is expected, along with aspects that may be adapted by local sites to aid implementation.
In partnership with multidisciplinary teams at each site, we will adapt clinical practices from other contexts and available information about SL-BUP and XR-BUP to site-specific clinical protocols and implementation strategies.
The study implementation facilitators will assist local champions to identify potential treatment providers and draw on existing resources for training and ongoing support.
|
Community Stakeholders
|
Implementation will include developing clinical protocols containing core components of the intervention to which fidelity is expected, along with aspects that may be adapted by local sites to aid implementation.
In partnership with multidisciplinary teams at each site, we will adapt clinical practices from other contexts and available information about SL-BUP and XR-BUP to site-specific clinical protocols and implementation strategies.
The study implementation facilitators will assist local champions to identify potential treatment providers and draw on existing resources for training and ongoing support.
|
Patients
ED patients will be recruited to participate in interviews or focus groups.
|
Implementation will include developing clinical protocols containing core components of the intervention to which fidelity is expected, along with aspects that may be adapted by local sites to aid implementation.
In partnership with multidisciplinary teams at each site, we will adapt clinical practices from other contexts and available information about SL-BUP and XR-BUP to site-specific clinical protocols and implementation strategies.
The study implementation facilitators will assist local champions to identify potential treatment providers and draw on existing resources for training and ongoing support.
The study implementation facilitators will assist local champions to identify potential treatment providers and draw on existing resources for training and ongoing support.
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Receipt of ED-initiated BUP (binary) and will be abstracted from the health record.
Tijdsspanne: 12 Months
|
Proportion receiving emergency department BUP amongst patients who have been determined to be eligible for and willing to receive ED-initiated BUP
|
12 Months
|
Secundaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
---|---|
Proportion of patients who received ED-initiated BUP who are engaged in formal addiction treatment 30 days after the index ED visit.
Tijdsspanne: 12 Months
|
12 Months
|
Medewerkers en onderzoekers
Sponsor
Medewerkers
Onderzoekers
- Hoofdonderzoeker: Ryan McCormack, MD, NYU Langone Health
Publicaties en nuttige links
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- 17-01513
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op Opioïdengebruikstoornis
-
University of HoustonOnbekend
-
New York City Health and Hospitals CorporationBeëindigdGlaucoom | Ziekte van het netvlies | Visuele Pathway DisorderVerenigde Staten
-
Neuro-Eye Diagnostic Systems, LLCNeuro-ophthalmology of Texas PLLCAanmelden op uitnodigingMacula ziekte | Visuele Pathway Disorder | Ziekte van de oogzenuwVerenigde Staten
-
Fondazione G.B. Bietti, IRCCSVoltooidGlaucoom | Optische neuropathie, ischemische | Optische zenuw | Visuele Pathway Disorder | Neurale geleidingItalië
-
University of MiamiNational Eye Institute (NEI)VoltooidGlaucoom | Maculaire degeneratie | Retinale degeneratie | Optische neuropathie | DrDeramus verdachte | Visuele Pathway DisorderVerenigde Staten
-
Isfahan University of Medical SciencesVoltooidZiekte van Tanger | Body Mass Index Quantitative Trait Locus 5 DisorderIran, Islamitische Republiek
-
Weill Medical College of Cornell UniversityUniversity of California, Los Angeles; University of Wisconsin, MilwaukeeVoltooidTourette syndroom | De stoornis van Gilles de la Tourette | Gilles de la Tourette | Gilles de la Tourette-syndroom | Ziekte van Gilles de la Tourette | Tourette-ziekte | Tic Disorder, Gecombineerde Vocale en Multiple Motor | Meerdere motorische en vocale ticstoornis, gecombineerd | Ziekte van Gilles... en andere voorwaarden